

2025

Gold MS, Milas B, Cutchins C, Walsh SL, Piotrowski J, Boyer EW. Overdose reversal challenges and priorities in the era of synthetic opioids: Insights from the RESPIRE Expert Forum. *Curr Addict Rep*. 2025 Apr 16;12(39). doi.org/10.1007/s40429-025-00648-5

Laffont CM, de la Peña A, Skolnick P. Translational modeling as a tool to evaluate the effectiveness of nalmefene in a community setting: A critical perspective [letter]. *Clin Pharmacol Ther*. doi.org/10.1002/cpt.3668 Epub. 2025 April 8.

Craft WH, Craft CL, Tegge AN, Athamneh LN, Stein JS, Keith DR, Le Moigne A, DeVeaugh-Geiss AM, Chilcoat HD, Bickel WK. Pain severity contributes to worse outcomes in opioid use disorder recovery than pain status. *Drug and Alcohol Dependence*. 2025 Feb;267:112530. doi.org/10.1016/j.drugalcdep.2024.112530. Epub 2025 Jan 3.

Lee K, Mead A, Ghauri I, Hollett B, Drolet M, Kozicky J. Initiation and dosing of extended-release buprenorphine: A narrative review of emerging approaches for patients who use fentanyl. *Subst Abuse Rehabil*. 2025 March 25;16:71–82.